Imuran (Azathioprine)

Azathioprine is a prodrug that is converted inside cells to 6‑mercaptopurine, which interferes with purine synthesis. This disruption hampers DNA and RNA production, limiting the proliferation of activated T and B lymphocytes. The resulting reduction in immune cell activity provides the immunosuppressive effect needed for transplant and autoimmune disease management.

The dosage of Imuran is individualized and set by the prescribing healthcare professional based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Imuran is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should only be used during pregnancy if the potential benefit justifies the risk, and under close medical supervision. Limited data are available for breastfeeding; the decision to continue should be made by a healthcare provider weighing infant exposure against maternal benefit.

To request Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any temperature requirements) and assists with import documentation.

Compared with alternatives such as mycophenolate mofetil or cyclosporine, azathioprine offers a well‑established efficacy profile for transplant and autoimmune indications but may have a slower onset of action. Its side‑effect spectrum differs, with notable risks of bone‑marrow suppression and hepatotoxicity, while other agents may have distinct renal or cardiovascular concerns. Choice depends on patient factors and physician judgment.

Imuran tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Imuran is taken orally as a tablet, usually with food or a glass of water to reduce gastrointestinal irritation. The exact timing (e.g., morning or evening) and whether it is taken with or without food should follow the prescribing clinician’s directions.

The most serious risks include bone‑marrow suppression leading to severe leukopenia, anemia or thrombocytopenia; hepatotoxicity that can progress to liver failure; opportunistic infections due to immunosuppression; and an increased long‑term risk of certain malignancies such as lymphomas and skin cancers. Regular laboratory monitoring is essential to detect these complications early.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or any of its components, those with active severe infections, and individuals with significant bone‑marrow failure or severe liver disease. Caution is also advised for patients with thiopurine methyltransferase (TPMT) deficiency, as they are at higher risk for toxicity.